CagriSema
vs Retatrutide.
Compare CagriSema and retatrutide by mechanism, Phase 3 trial design, reported weight loss, adverse-event context, FDA status, and evidence limits.
Also searched as CagriSema vs Retatrutide results · Cagrilintide plus Semaglutide vs triple agonist
CagriSema vs Retatrutide: What is the difference?
CagriSema and retatrutide are advanced but different investigational obesity drugs, and no head-to-head trial has compared them. CagriSema combines cagrilintide with semaglutide in a once-weekly injection and has been submitted to the FDA. Retatrutide is a once-weekly triple agonist targeting GIP, GLP-1, and glucagon receptors and has reported Phase 3 topline results. CagriSema is not approved merely because an application was filed, retatrutide is not approved, and separate trial percentages cannot determine which drug is better.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
CagriSema
Submitted to FDA - not yet approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 30 matched NCT records
- Sponsor
- Novo Nordisk
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
CagriSema vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between CagriSema and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
CagriSema
Amylin analogue + GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 / US regulatory review
- Status
- Submitted to FDA - not yet approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 5
- Results posted
- 0
- Recruiting site observations
- 155
matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Answer the question without inventing a winner.
Each answer keeps route, mechanism, development stage, and trial result attached to the evidence that produced the fact.
Is CagriSema better than Retatrutide?
No randomized head-to-head trial establishes CagriSema or Retatrutide as better. CagriSema combines cagrilintide and semaglutide and has an FDA application under review. Retatrutide is one triple-agonist molecule with reported Phase 3 results. The often-compared 22.7% and 28.3% figures use different trials, durations, protocols, and efficacy estimands, so the numerical gap is not a superiority result.
Does CagriSema preserve more muscle than Retatrutide?
The current cited evidence does not establish that CagriSema preserves more muscle than Retatrutide. Body-composition findings, treatment discontinuation, dose escalation, population, and analysis method must come from comparable protocols before a muscle-preservation claim can be supported. Neither mechanism nor the addition of an amylin analogue proves a comparative lean-mass benefit on its own.
CagriSema
Amylin analogue + GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 / US regulatory review
- Status
- Submitted to FDA - not yet approved
- Featured trial anchors
- NCT05567796 · NCT05669755 · NCT07011667
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
Both programs now have large Phase 3 weight-management datasets, so their headline percentages are frequently placed side by side. The more defensible comparison keeps the REDEFINE 1 treatment-policy and trial-product estimates separate from the TRIUMPH-1 treatment-regimen and efficacy estimates, then checks the different populations, durations, doses, adverse-event reporting, and regulatory milestones.
| Field | CagriSema | Retatrutide | How to interpret it |
|---|---|---|---|
| Drug design | Fixed-dose cagrilintide plus semaglutide combination | Single GIP, GLP-1, and glucagon triple agonist | One combines two active molecules; the other integrates three receptor activities in one molecule. |
| Pivotal anchor | 22.7% at 68 weeks under the REDEFINE 1 trial-product estimand | 28.3% at 80 weeks under the TRIUMPH-1 efficacy estimand | The values come from separate trials with different durations and cannot support a head-to-head ranking. |
| Regulatory status | New Drug Application submitted to the FDA in December 2025 | Investigational Phase 3 program; no approval recorded | Submission is a concrete milestone, but it is not approval, launch, price, or coverage. |
| Route studied | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection | A shared weekly route does not make the formulations, escalation schedules, or safety profiles equivalent. |
Why the headline numbers do not name a winner.
REDEFINE 1 reported 20.4% mean loss regardless of treatment adherence and 22.7% if participants stayed on treatment at 68 weeks. TRIUMPH-1 reported 25.0% for the 12 mg group regardless of adherence and 28.3% under the efficacy estimand at 80 weeks. The estimands are conceptually related but the trials were not randomized against each other, so the numerical gap is not proof of superiority.
Keep the comparison honest.
- 01
Compare matching estimand concepts before comparing percentages, and still treat the result as cross-trial context only.
- 02
Keep CagriSema's FDA submission separate from an approval decision, commercial launch, insurance coverage, or pharmacy access.
- 03
Read adverse-event and discontinuation data inside each trial rather than claiming one program is safer from unrelated reports.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →